Skip to main
ACTU

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics has demonstrated promising clinical results for elraglusib in treating first-line metastatic pancreatic adenocarcinoma, with data showing significant improvements in median overall survival (mOS) and one-year survival rates compared to standard treatments. The company's recent fundraising has strengthened its balance sheet, enabling management to explore regulatory pathways without financial constraints while funding operational costs associated with upcoming clinical studies. Given the potential for elraglusib to achieve a positive regulatory decision with further validation in larger trials, optimism remains high regarding the company's future growth and development prospects.

Bears say

Actuate Therapeutics Inc is currently in the clinical stage of drug development with elraglusib targeting difficult-to-treat cancers, but recent financial reports indicate a concerning trend of increasing operational expenses that may outpace revenue growth. Additionally, the company faces significant risks associated with clinical trial outcomes and regulatory approvals, which could further strain its financial position due to the high costs of research and development. Lastly, limited market presence and potential competition in the biopharmaceutical sector heighten the uncertainty surrounding the viability and commercial success of its therapeutic candidates.

ACTU has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACTU has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.